Overview

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Status:
Recruiting

Trial end date:
2022-07-08

Target enrollment:

Participant gender:

Summary

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

Phase:

Phase 3

Details

Lead Sponsor:

Cynapsus Therapeutics Inc
Sunovion

Treatments:

Apomorphine